Substituted Tetracycline Compounds for Resistant Bacillus anthracis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Bacillus anthracis infections, including those potentially used in bioterrorism scenarios, face challenges due to antibiotic resistance, with existing antibiotics like ciprofloxacin and doxycycline becoming less effective as resistance develops, necessitating the need for novel, effective agents.
Innovation Solution
Development of novel, narrow-spectrum, orally bioavailable substituted tetracycline compounds that are active against Bacillus anthracis, including strains resistant to known tetracycline resistance elements, which are administered to treat and prevent infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics (ciprofloxacin, doxycycline, penicillin G procaine) are used for anthrax treatment, then current standard therapy is maintained, but antibiotic resistance develops reducing effectiveness
Solution Approach 1:
The patent applies parameter changes by chemically modifying the tetracycline molecule structure - specifically substituting groups at the 7-position (e.g., dimethylamino, hydroxy, amino) and 9-position (e.g., amino, hydroxy) to create novel compounds with altered pharmacological properties that overcome resistance mechanisms while maintaining antibacterial activity against B. anthracis
Solution Approach 2:
The invention creates composite antibiotic agents by combining the core tetracycline structure with various substituent groups (dimethylamino, hydroxy, amino at different positions) to produce a series of compounds with enhanced and differentiated spectra of activity, including activity against resistant strains
2Reliability
If broad-spectrum antibiotics are used to ensure coverage, then treatment effectiveness is maintained, but resistance determination becomes more complex and narrow-spectrum agents are needed
Solution Approach 1:
The patent applies local quality by creating narrow-spectrum tetracycline derivatives with specific substituent patterns (e.g., 7-dimethylamino-9-amino substitutions) that provide targeted activity against B. anthracis while maintaining resistance to common resistance mechanisms, thereby simplifying resistance determination and reducing the need for broad-spectrum coverage
3Reliability
If novel substituted tetracycline compounds are developed, then activity against resistant strains is improved, but oral bioavailability and pharmacokinetic properties must be optimized
Solution Approach 1:
The patent applies parameter changes by systematically varying substituent groups at key positions (7 and 9) to optimize both antibacterial activity against resistant strains and pharmacokinetic properties including oral bioavailability, absorption, distribution, metabolism, and excretion characteristics
Data Source
AI summary
Methods and compositions for the treatment of Bacillus anthracis infections are described.